Palbociclib has a unique mechanism of action which helps in delaying disease progression when co-administered with hormonal therapies
Swiftmelt 1515-I meets performance requirements and secures skin attachment
Launch of Apollo Genomics Institutes would provide genetic counselling, tests, treatment and care for genetic disorders
Collaboration to generate and develop therapeutics for oncology and non-oncology conditions
Moderna and Merck announced mRNA-4157/V940, in combination with KEYTRUDA, demonstrated a 44% reduction in the risk of disease recurrence or death in melanoma patients
NDM disorders are a group of rare, inherited neuromuscular disorders with an estimated prevalence of 1 case per 100,000 inhabitants in Spain, and are characterized by the inability to relax muscles following voluntary contraction (myotonia)
The objective of this system is to shift the focus of measuring performance of hospitals from volume of services provided to value of healthcare services
The centre has initiated next generation sequencing (NGS) as a tool for undertaking studies on genomic epidemiology of pathogens
Dr. Jain is a biotechnology industry veteran with more than two decades of experience in pharmaceutical development across her time with ChemoCentryx, AbbVie, Abbott Laboratories, and G.D. Searle and Co
Advanz Pharma will leverage its specialty, hospital, and rare disease expertise and infrastructure to commercialize AT-007 in Europe for both Galactosemia and SORD Deficiency
Subscribe To Our Newsletter & Stay Updated
